Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors-Reference-Cited by-同舟云学术

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors

Published:2006 Issue:10 Volume:107 Page:2474-2481
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bajetta Emilio,Procopio Giuseppe,Catena Laura,Martinetti Antonia,De Dosso Sara,Ricci Sergio,Lecchi Alberto S.,Boscani Paolo F.,Iacobelli Stefano,Carteni Giacomo,De Braud Filippo,Loli Paola,Tartaglia Andreas,Bajetta Roberto,Ferrari Leonardo

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference19 articles.

1. Carcinoid tumour

2. [111In-DTPA-D-Phe1]Octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment

3. Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

4. Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms;Therapeutic Advances in Medical Oncology;2024-01

2. Sex differences in carcinoid syndrome: A gap to be closed;Reviews in Endocrine and Metabolic Disorders;2022-03-16

4. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review;Comprehensive Psychiatry;2021-08

5. The Effect of Pituitary Gland Disorders on Glucose Metabolism: From Pathophysiology to Management;Hormone and Metabolic Research;2020-10-12